Table 3 Baseline clinical characteristics based on primary KIT mutational statusa
Characteristic | Absent (n = 23) | Exon 9 (n = 42) | Exon 11 (n = 143) | Exon 13 (n = 5) | Exon 17 (n = 6) | Wild-type (n = 9) |
|---|---|---|---|---|---|---|
Age, median (range), years | 54 (11–67) | 58 (26–79) | 61 (27–83) | 67 (31–75) | 62 (44–79) | 46 (33–64) |
Male sex, n (%) | 10 (43) | 29 (69) | 88 (62) | 4 (80) | 3 (50) | 4 (44) |
ECOG performance status,b n (%) | ||||||
0 | 10 (43) | 20 (48) | 50 (35) | 1 (20) | 3 (50) | 2 (22) |
1 | 9 (39) | 17 (40) | 73 (51) | 4 (80) | 3 (50) | 7 (78) |
2 | 4 (17) | 4 (10) | 16 (11) | 0 | 0 | 0 |
3 | 0 | 0 | 3 (2) | 0 | 0 | 0 |
4 | 0 | 0 | 0 | 0 | 0 | 0 |
Time since original diagnosis, median (range), weeks | 92 (12–310) | 142 (22–702) | 209 (16–680) | 118 (33–236) | 197 (21–545) | 177 (30–773) |
Maximum prior imatinib dose, n (%) | ||||||
≤ 400 mg | 8 (35) | 10 (24) | 51 (36) | 0 | 0 | 2 (22) |
> 400–600 mg | 7 (30) | 8 (19) | 37 (26) | 4 (80) | 2 (33) | 0 |
> 600–800 mg | 8 (35) | 24 (57) | 53 (37) | 1 (20) | 4 (67) | 7 (78) |
> 800 mg | 0 | 0 | 2 (1) | 0 | 0 | 0 |
Outcome with prior imatinib therapy,c n (%) | ||||||
PD within 6 months of start | 10 (43) | 10 (24) | 4 (3) | 2 (40) | 1 (17) | 3 (33) |
PD beyond 6 months of start | 12 (52) | 26 (62) | 131 (92) | 3 (60) | 3 (50) | 4 (44) |
Intolerance | 1 (4) | 6 (14) | 8 (6) | 0 | 2 (33) | 2 (22) |
Best response to prior imatinib,d n (%) | ||||||
CR | 0 | 2 (5) | 6 (4) | 0 | 0 | 0 |
PR | 3 (13) | 7 (17) | 68 (48) | 0 | 3 (50) | 1 (11) |
Stable disease | 9 (39) | 22 (52) | 51 (36) | 2 (40) | 2 (33) | 6 (67) |
PD | 10 (43) | 10 (24) | 14 (10) | 3 (60) | 1 (17) | 1 (11) |
Not applicable | 1 (4) | 1 (2) | 4 (3) | 0 | 0 | 0 |